RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...
Moderna (NasdaqGS:MRNA) announced a collaboration with Recordati to develop and commercialize mRNA-3927 for propionic ...
Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...
Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...
Cholesterol bloodstream The FDA has granted Fast Track designation to mRNA-3927 (Moderna), an investigational mRNA therapeutic for propionic acidemia. The Food and Drug Administration (FDA) has ...
CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, ...
Metabolic cardiomyopathy is an important diagnostic consideration in a young patient with unexplained ventricular dysfunction or sudden cardiac arrest. Propionic acidemia is an uncommon but important ...
Propionic acidemia is caused by mutations in an enzyme called propionyl-CoA carboxylase. CoA is a helper molecule essential for energy metabolism. Propionic acidemia is typically managed by diet. The ...
BURLINGAME, CA, UNITED STATES, December 8, 2024 /EINPresswire / -- According to a new report published by CoherentMI The propionic acidemia therapeutic market is estimated to be valued at USD 600.6 Mn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results